XNAS
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.21 | -0.18 | +14.29% | $0 | ✅ Beat | +1.57% | +5.87% | — |
| 2026-03-25 | Q4 2025 | -0.16 | -0.28 | -75.00% | $0 | ❌ Miss | +1.57% | -3.25% | +10.55% |
| 2025-11-07 |
| Q3 2025 |
| -0.18 |
| -0.24 |
| -33.33% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | -0.16 | -0.22 | -37.50% | $0 | ❌ Miss | +0.00% | -5.02% | -9.21% |
| 2024-08-12 | Q2 2024 | -0.21 | -0.15 | +28.57% | $0 | ✅ Beat | +0.54% | +12.97% | +0.54% |
| 2024-03-29 | Q4 2023 | -0.23 | -0.24 | -4.35% | $0 | ❌ Miss | — | — | — |
| 2023-11-13 | Q3 2023 | -0.23 | -0.23 | +0.00% | $0 | ➖ Inline | +3.53% | +3.76% | -1.88% |
| 2023-08-11 | Q2 2023 | -0.17 | -0.24 | -41.18% | $0 | ❌ Miss | +0.55% | -4.95% | +56.04% |
Showing last 8 quarters.